Extending aromatase inhibitor duration to 10 years lowers recurrence for ER/PR+ breast cancer patients
Full article:

Hormonal therapy reduces the risk of recurrence for women with early-stage breast cancer that is ER-and/or PR-positive. Standard therapy lasts 5 years. A new study looks at whether extending one type of hormonal therapy, known as aromatase inhibitor therapy, to 10 years lowers recurrence rates even more for these women. (7/26/16)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies enrolling people with early stage ER-positive, HER2-negative breast cancer. 

A number of other clinical trials for patients with early-stage breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.